RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy
Cells · 2023
DOI: 10.3390/cells12111538 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Laetitia Marcadet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre Hospitalier Universitaire de Québec, Centre de Recherche du Centre Hospitalier de l'Université Laval (CHUQ-CHUL), Axe Neurosciences, Universit…. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Cardiomyopathy has become one of the leading causes of death in patients with Duchenne muscular dystrophy (DMD). We recently reported that the inhibition of the interaction between the receptor activator of nuclear factor κB ligand (RANKL) and receptor activator of nuclear factor κB (RANK) significantly improves muscle and bone functions in dystrophin-deficient mdx mice. RANKL and RANK are also expressed in cardiac muscle. Here, we investigate whether anti-RANKL treatment prevents cardiac hypertrophy and dysfunction in dystrophic mdx mice. Anti-RANKL treatment significantly reduced LV hypertrophy and heart mass, and maintained cardiac function in mdx mice. Anti-RANKL treatment also inhibited NFκB and PI3K, two mediators implicated in cardiac hypertrophy. Furthermore, anti-RANKL treatment increased SERCA activity and the expression of RyR, FKBP12, and SERCA2a, leading possibly to an improved Ca2+ homeostasis in dystrophic hearts. Interestingly, preliminary post hoc analyses suggest that denosumab, a human anti-RANKL, reduced left ventricular hypertrophy in two patients with DMD. Taken together, our results indicate that anti-RANKL treatment prevents the worsening of cardiac hypertrophy in mdx mice and could potentially maintain cardiac function in teenage or adult patients with DMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre Hospitalier Universitaire de Québec, Centre de Recherche du Centre Hospitalier de l'Université Laval (CHUQ-CHUL), Axe Neurosciences, Université Laval, Quebec City, QC G1V 4G2, Canada.
- Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
- The Ottawa Pediatric Bone Health Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.
- Department of Immunology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan.
- The Department of Pediatrics, University of Ottawa, Ottawa, ON K1H 8L1, Canada.
- Department of Rehabilitation, Université Laval, Quebec City, QC G1V 0A6, Canada.
ORCID-Profile: Laetitia Marcadet, A Russell Tupling, Jérôme Frenette
Förderung
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- Canadian Institutes of Health Research
Zitieren
APA
Marcadet, L., Juracic, E. S., Khan, N., Bouredji, Z., Yagita, H., Ward, L. M., Tupling, A. R., Argaw, A., & Frenette, J. (2023). RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy. Cells. https://doi.org/10.3390/cells12111538
Vancouver
Marcadet L, Juracic ES, Khan N, Bouredji Z, Yagita H, Ward LM, et al. RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy. Cells. 2023. doi:10.3390/cells12111538
BibTeX
@article{Marcadet2023,
author = {Marcadet, Laetitia and Juracic, Emma Sara and Khan, Nasrin and Bouredji, Zineb and Yagita, Hideo and Ward, Leanne M and Tupling, A Russell and Argaw, Anteneh and Frenette, Jérôme},
title = {RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12111538}
}
EUVIMED